Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent cause of Parkinson’s disease (PD) with late-onset and autosomal-dominant inheritance. LRRK2 belongs to the ROCO superfamily of proteins, characterized by a Ras-of-complex (Roc) GTPase domain in tandem with a C-terminal-of-Roc (COR) domain. LRRK2 also contains a protein kinase domain adjacent to the Roc-COR tandem domain in addition to multiple repeat domains. Disease-causing familial mutations cluster within the Roc-COR tandem and kinase domains of LRRK2, where they act to either impair GTPase activity or enhance kinase activity. Familial LRRK2 mutations share in common the capacity to induce neuronal toxicity in cultured cells. While the contribution of the frequent G2019S mutation, located within the kinase domain, to kinase activity and neurotoxicity has been extensively investigated, the contribution of GTPase activity has received less attention. The GTPase domain has been shown to play an important role in regulating kinase activity, in dimerization, and in mediating the neurotoxic effects of LRRK2. Accordingly, the GTPase domain has emerged as a potential therapeutic target for inhibiting the pathogenic effects of LRRK2 mutations. Many important mechanisms remain to be elucidated, including how the GTPase cycle of LRRK2 is regulated, whether GTPase effectors exist for LRRK2, and how GTPase activity contributes to the overall functional output of LRRK2. In this review, we discuss the importance of the GTPase domain for LRRK2-linked PD focusing in particular on its regulation, function, and contribution to neurotoxic mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 2×
“So far, most studies have highlighted the kinase activity of LRRK2 as a key therapeutic target since the most common G2019S mutation elevates kinase activity and induces neuronal toxicity in a kinase-dependent manner [18, 34, 40, 57].”
Self-citation(2007) · YUHSpace (Yonsei University Medical Library) · doi:10.1016/s1474 · Cited by 641
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2006) · Nature Neuroscience · doi:10.1038/nn1776 · Cited by 619 · cited 11×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript pharmacological inhibition of kinase activity has been proven to be protective in viral-based G2019S LRRK2 rodent models [57, 71] and also protects against neurodegeneration induced by human α-synuclein or LPS-induced neuroinflammation in…”
BackgroundInfluentialRamonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018568 · Cited by 405
Self-citation
Cited by
Taylor, M., & Alessi, D. R. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.01.001 · Cited by 141
Arrazola Sastre, A., Luque Montoro, M., Gálvez-Martín, P., Lacerda, H. M., Lucia, A., Llavero, F., & Zugaza, J. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176312 · Cited by 103
“In contrast, little attention has been paid to the effects of this mutation on the GTPase activity when it is known that the GTPase domain plays an important role in the regulation of the kinase activity and its neurotoxic effects [57].”
BackgroundPathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations
Chen, C., Soto, G., Dumrongprechachan, V., Bannon, N., Kang, S., Kozorovitskiy, Y., & Parisiadou, L. (2020) · eLife · doi:10.7554/elife.58997 · Cited by 56
Heaton, G. R., Landeck, N., Mamais, A., Nalls, M. A., Nixon-Abell, J., Kumaran, R., Beilina, A., Pellegrini, L., Li, Y., Harvey, K., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104948 · Cited by 43
Endosomal sorting pathways in the pathogenesis of Parkinson's disease
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2020.02.001 · Cited by 25
Metadata
- Authors
- Nguyen, A. P. T., & Moore, D. J.
- Venue
- Advances in Neurobiology
- Publisher
- Springer International Publishing
- Published
- 2017
- Volume
- 14
- Pages
- 71-88
- ISSN
- 2190-5215 (ISSN-L)
- 2190-5223
- OpenAlex
- W2598412882
- Cited by
- 59
- References
- 5
- FWCI
- 12.84
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity. https://app.cochat.ai/papers/10.1007/978-3-319-49969-7_4
- The paper
- Nguyen, A. P. T., & Moore, D. J. (2017). Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity. Advances in Neurobiology. https://doi.org/10.1007/978-3-319-49969-7_4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.